Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• having coexisting cardiovascular disease or a history of cardiovascular diseases

• having electrocardiogram record conducted within seven days before the start of the mirabegron treatment (including the first day of administration)

Exclusion Criteria:

• having serious cardiovascular disease

• having significant long QT (QTc > 500 msec)